Evidence map›Paper›PMID 41896302›Full record

ArticleInflammation research : official journal of the European Histamine Research Society ... [et al.]2026

TET1 deficiency amplifies macrophage inflammatory signaling associated with Crohn's disease.

Rocio K Perez, Reeba Paul, Parveen Kumar, Alp Tutkun, Deborah Webb, Shea McGorty, Thomas Wieckowski, Yoon Sing Yap, Tiffany E Leesang, Panayiotis I Vlantis and 5 more

Abstract read
In one paragraph

Article in Inflammation research : official journal of the European Histamine Research Society ... [et al.], 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Rocio K PerezImmunology and Respiratory Department, Boehringer Ingelheim Pharmaceuticals, Inc, Ridgefield, CT, USA.
Reeba PaulComputational Biology and Digital Sciences Department, Boehringer Ingelheim Pharmaceuticals, Inc, Ridgefield, CT, USA.
Parveen KumarComputational Biology and Digital Sciences Department, Boehringer Ingelheim Pharmaceuticals, Inc, Ridgefield, CT, USA.
Alp TutkunComputational Biology and Digital Sciences Department, Boehringer Ingelheim Pharmaceuticals, Inc, Ridgefield, CT, USA.
Deborah WebbImmunology and Respiratory Department, Boehringer Ingelheim Pharmaceuticals, Inc, Ridgefield, CT, USA.
Shea McGortyImmunology and Respiratory Department, Boehringer Ingelheim Pharmaceuticals, Inc, Ridgefield, CT, USA.
Thomas WieckowskiImmunology and Respiratory Department, Boehringer Ingelheim Pharmaceuticals, Inc, Ridgefield, CT, USA.
Yoon Sing YapDepartment of Biochemistry and Molecular Biology, University of Miami, Miller School of Medicine, FL, Miami, USA.
Tiffany E LeesangDepartment of Biochemistry and Molecular Biology, University of Miami, Miller School of Medicine, FL, Miami, USA.
Panayiotis I VlantisDepartment of Biochemistry and Molecular Biology, University of Miami, Miller School of Medicine, FL, Miami, USA.
Aristeidis G TelonisDepartment of Biochemistry and Molecular Biology, University of Miami, Miller School of Medicine, FL, Miami, USA.
Christine HajdinComputational Biology and Digital Sciences Department, Boehringer Ingelheim Pharmaceuticals, Inc, Ridgefield, CT, USA.
Jim KingImmunology and Respiratory Department, Boehringer Ingelheim Pharmaceuticals, Inc, Ridgefield, CT, USA.
Gerald NaboznyImmunology and Respiratory Department, Boehringer Ingelheim Pharmaceuticals, Inc, Ridgefield, CT, USA.
Luisa CimminoDepartment of Biochemistry and Molecular Biology, University of Miami, Miller School of Medicine, FL, Miami, USA. luisa.cimmino@med.miami.edu.

Funding

Enhancing TET activity for the treatment of hematological malignancyR01CA282453 · NCI · UNIVERSITY OF MIAMI SCHOOL OF MEDICINE · PI Luisa Cimmino · 2023 to 2026
$1.4M
NCI NIH HHS R01 CA282453NCI NIH HHS R01CA282453
6 · The paper itself

Abstract

OBJECTIVE AND

designTo define the role of Ten-Eleven Translocation (TET) proteins in Crohn's disease (CD)-associated inflammation through integrative human and mechanistic studies. MATERIAL: Publicly available CD transcriptomic and DNA methylation datasets, and primary mononuclear cells and ileal biopsies were analyzed for TET gene expression and signatures. TET1 and TET2 CRISPR/Cas9 knockout macrophage cell lines were generated. TREATMENT: Macrophages were stimulated with LPS in the presence or absence of kinase inhibitors. Conditioned media from macrophages were applied to primary human neutrophils. PBMCs from CD patients and healthy donors were stimulated with LPS for validation.

methodsMacrophages or primary patients samples were analyzed by high-throughput surface marker profiling, RNA sequencing, 5hmC sequencing, assays of effector function, qRT-PCR, phosphoflow, and cytokine/chemokine release by ELISA.

resultsTET1 was the most downregulated TET enzyme in CD blood and ileal tissues, correlating with reduced TET-associated gene signatures and elevated inflammatory mediators. TET1-deficient macrophages exhibited distinct surface phenotypes, reduced PTEN expression, altered 5hmC distribution, and heightened IFN gene expression, ERK activation, and chemokine release associated with enhanced neutrophil migration. PBMCs from CD patients mirrored reduced TET1 expression and exaggerated inflammatory responses.

conclusionsTET1 functions as a non-redundant regulator of inflammatory macrophages and aberrant chemokine signaling linked to immune cell recruitment in Crohn's disease.

Indexed as

Crohn DiseaseDNA-Binding ProteinsMacrophagesMixed Function OxygenasesProto-Oncogene ProteinsCytokinesDioxygenasesFemaleHumansIleumInflammationNeutrophilsSignal TransductionCytokinesDioxygenasesDNA-Binding ProteinsMixed Function OxygenasesProto-Oncogene ProteinsTET1 protein, humanTET2 protein, humanCCL-8Crohn’s diseaseInflammatory macrophagesNeutrophil migrationTET1

Identifiers

PMID41896302
PMCPMC13031220

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.